A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients with Narcolepsy
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2019
At a glance
- Drugs TAK-925 (Primary)
- Indications Narcolepsy
- Focus Adverse reactions
- Sponsors Takeda Pharma
- 05 Feb 2019 Part A' is an open-label has added in the study, number of treatment arms has been changed from 15 to 17 and also planned patient number increased
- 05 Feb 2019 Planned number of patients changed from 84 to 96.
- 05 Dec 2018 Status changed from not yet recruiting to recruiting.